Page 5 - தேசிய ஆரோக்கியம் ஆராய்ச்சி நிறுவனங்கள் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Revive Therapeutics files Orphan Drug Designation application with FDA for Psilocybin to treat moderate to severe traumatic brain injury (TBI) Michael Frank, CEO of Revive commented: “The FDA orphan drug application for psilocybin to treat moderate to severe TBI is an important milestone for Revive as we focus on building a robust product pipeline focused on novel uses and delivery forms of psilocybin to treat significant unmet medical needs Approximately 50% of people with severe TBI will experience further decline in their daily lives or die within 9 years of their injury Revive Therapeutics Ltd. (CSE:RVV) (OTCMKTS:RVVTF) said it has filed an application with the US Food and Drug Administration (FDA) to receive Orphan Drug Designation (ODD) for Psilocybin to treat moderate to severe traumatic brain injury (TBI).

United statesMichael frankNational health research institutesPharmather holdings ltdPsilocin pharma corpTherapeutics ltdDrug administrationRevive therapeuticsOrphan drug designationPharmather holdingsOrphan drug actDrug applicationOrphan drugFast trackBreakthrough therapyRare pediatric disease